Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00245648
Status:
COMPLETED
Last Update Posted:
2012-10-04
First Post:
2005-10-27
Brief Title:
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI
Sponsor:
NYU Langone Health
Organization:
NYU Langone Health
Study Overview
Official Title:
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial
Status:
COMPLETED
Status Verified Date:
2012-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluated differences between men and women in the presentation management and outcome of heart attacks within the GUSTO V study
Detailed Description:
The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes GUSTO V trial examined a large contemporary cohort of women and men with ST elevation myocardial infarction STEMI treated with fibrinolytic therapy The objective of the present study was to evaluate sex differences in presentation management and outcome in GUSTO V
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None